Recent acquisitions and our ongoing expansion efforts have laid the groundwork for a robust product pipeline. With an accelerated commitment to enhancing our capabilities with additional dosage forms and a focus on novel development and ANDA manufacturing, our pipeline is well-rounded and continues to grow.
Chartwell is aggressively seeking product acquisitions. If you have an asset that no longer fits your portfolio, please contact us to discuss how to maximize your opportunity.
We are well-prepared to sell to government entities
and supply state and federal contracts:
Trade Agreements Act (TAA)
compliant production
Quick ramp-up of production
with available surge capacity
Focus on extended dating
program allows maximization
of investment of government
funds
Recent acquisitions and our ongoing expansion efforts have laid the groundwork for a robust product pipeline. With an accelerated commitment to enhancing our capabilities with additional dose forms and a focus on novel development and ANDA manufacturing, our pipeline is well-rounded and continues to grow.
There’s plenty on the horizon for Chartwell Pharmaceuticals LLC:
Over 20 product launches anticipated in the coming 9 months
Pipeline of over 700 Orange Book listings
Capabilities for additional dosage forms currently being built out
Development of additional 505(b)(2) products underway
To explore how we can help,
please contact us at: [email protected]
Chartwell Pharmaceuticals LLC.
Phone: 845-268-5000
Headquarters
77 Brenner Drive
Congers, NY 10920
Amityville Location
Carmel Location
